Nanoscan (Human Serum Albumin)

Human serum albumin increases plasma oncotic pressure by remaining in the vascular compartment and drawing water from the interstitial space into the bloodstream. This expands circulating volume, improves tissue perfusion, and also binds various endogenous substances, aiding their transport and stability.

The dose of Nanoscan is individualized by the prescribing clinician based on the patient’s clinical condition, weight, serum albumin level, and target volume expansion. Dosing regimens are determined at the point of care and should follow the prescriber’s instructions.

Safety data for Nanoscan in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Nanoscan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Compared with crystalloid solutions, Nanoscan provides a higher oncotic pressure, leading to more efficient intravascular volume expansion with less overall fluid volume. Relative to other albumin products, it offers comparable efficacy; choice often depends on formulation, regulatory status, and supply considerations.

Nanoscan must be stored at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the product in its original packaging until use, and monitor temperature during transport to maintain the cold‑chain requirements.

Nanoscan is administered by intravenous or subcutaneous injection. The infusion rate should follow the prescribing information, typically over several minutes for IV use, to reduce the risk of hypotension. Subcutaneous administration is given as a slow injection into the appropriate tissue layer.

Serious risks include anaphylactic reactions, volume overload leading to pulmonary edema, hemolysis, thromboembolic events, acute renal dysfunction, and severe hypotension. Immediate medical attention is required if any of these events are suspected.

Nanoscan is contraindicated in patients with known hypersensitivity to human serum albumin or any component of the formulation, and in those with uncontrolled heart failure where volume overload could be life‑threatening. Caution is also advised for patients with severe renal impairment.